Fall risk and gait in Parkinson's disease: The role of the LRRK2 G2019S mutation. Issue 12 (7th October 2013)

• Record Type: Journal Article
• Authors: Mirelman, Anat; Heman, Talia; Yasinovsky, Kira; Thaler, Avner; Gurevich, Tanya; Marder, Karen; Bressman, Susan; Bar‐Shira, Anat; Orr‐Urtreger, Avi; Giladi, Nir; Hausdorff, Jeffrey M.
• Is Part Of: Movement disorders. Volume 28:Issue 12(2013)
• Page Start: 1683
• Page End: 1690
• Publication Date: 2013-10-07
• Subjects: Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.25587
• Languages: English
• ISSNs: 0885-3185

Abstract

<abstract abstract-type="main"> <title>ABSTRACT</title> <p>Patients with Parkinson's disease (PD) who carry the G2019S mutation (a glycine to serine substitution at amino acid 2019) in the leucine‐rich repeat kinase 2 (<italic>LRRK2</italic>) gene are generally believed to be clinically indistinguishable from patients with sporadic PD. There are, however, conflicting reports on the relationship between the mutation and the motor phenotype. We quantitatively compared gait and mobility in patients with PD carriers of the G2019S mutation to non‐carrier patients with PD to better understand the genotype‐phenotype relationship. Fifty patients with PD carriers of the G2019S <italic>LRRK2</italic> mutation and 50 age, disease duration, and disease severity matched PD non‐carriers were studied. An accelerometer quantified gait under three walking conditions: usual‐walking, dual‐tasking, and fast‐walking. The Unified Parkinson's Disease Rating Scale classified patients into PD sub‐types and the Timed Up and Go quantified mobility and fall risk. In all three walking conditions, gait variability was larger and the walking pattern was less consistent among the PD mutation carriers (<italic>P</italic> < 0.016). The PD carriers also took longer to complete the Timed Up and Go (<italic>P</italic> = 0.011) and were more likely to report having fallen in the previous year (<italic>P</italic> = 0.018). 64% of the PD carriers were classified as belonging to the postural‐instability‐gait‐difficulty (PIGD) sub‐type compared to only 17% of the PD non‐carriers (<italic>P</italic> < 0.0001). Among patients with PD, the G2019S mutation in the <italic>LRRK2</italic> gene is apparently associated with increased gait variability, an increased fall risk, and the PIGD sub‐type. Therapeutic approach specifically designed to delay gait disturbances and falls may be justified in patients who carry the G2019S mutation. © 2013 International Parkinson and Movement Disorder Society</p> </abstract>